Wall Street Zen Upgrades Cardio Diagnostics (NASDAQ:CDIO) to Hold

Posted by Paula Ricardo on Mar 23rd, 2026

Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cardio Diagnostics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cardio Diagnostics has a consensus rating of “Sell”.

Check Out Our Latest Stock Report on CDIO

Cardio Diagnostics Stock Performance

Shares of CDIO stock opened at $2.29 on Friday. Cardio Diagnostics has a 52-week low of $0.97 and a 52-week high of $17.39. The firm has a market capitalization of $6.78 million, a P/E ratio of -0.62 and a beta of 2.25. The stock has a 50 day moving average price of $2.65 and a 200 day moving average price of $3.27.

Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) last posted its quarterly earnings data on Friday, March 13th. The company reported ($0.80) earnings per share (EPS) for the quarter. Cardio Diagnostics had a negative net margin of 40,612.50% and a negative return on equity of 71.75%. As a group, sell-side analysts forecast that Cardio Diagnostics will post -0.55 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cardio Diagnostics stock. Citadel Advisors LLC acquired a new position in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned 1.07% of Cardio Diagnostics as of its most recent SEC filing. Institutional investors own 8.06% of the company’s stock.

About Cardio Diagnostics

(Get Free Report)

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.